Objectives. Serum immunoglobulin free light chains (FLCs) are frequently elevated in B-cell-mediated autoimmune diseases, including primary SS (pSS). The objective of this study was to assess if serum FLCs can contribute to classification, mucosa-associated lymphoid tissue (MALT) lymphoma detection, monitoring of disease activity and treatment response in pSS.
intracellular levels of Bruton's tyrosine kinase in naive and memory B cells further reflect their intrinsic, more activated state [2] . Also, pSS patients have an enhanced risk of developing mucosa-associated lymphoid tissue (MALT) lymphoma, a subclass of malignant B cell lymphoma [1, 3] . In line with this role for B cells in pSS pathogenesis, B cell depletion therapy with rituximab shows favourable effects on salivary gland architecture and extraglandular manifestations of pSS [4] . However, not all patients benefit from this treatment, as shown by two large randomized controlled trials [5, 6] . Validated biological markers for monitoring clinical response to therapy and/or disease activity in pSS are lacking. Promising markers are serological parameters of B cell activity, including BAFF (B cell activation of the TNF family, also named BLyS), CXCL13, b2-microglobulin and immunoglobulin free light chains (FLCs). These markers are fairly associated with systemic disease activity in pSS patients [7, 8] .
FLCs comprise k and light chains, which are produced in excess compared with heavy chains during immunoglobulin synthesis by B cells, plasmablasts and plasma cells. The surplus of light chains is secreted as FLCs into serum [9] . The half-life of FLCs in serum is very short (26 h) compared with complete immunoglobulins and therefore the presence of FLCs may reflect actual B cell activity. FLCs may have specific biological functions, which include binding to antigens on antigen-presenting cells and inhibition of apoptosis of neutrophils [1012] . FLC serum levels correlate positively with other serological markers of B cell activity and most strongly with serum IgG [13] . Levels of polyclonal FLCs are not only elevated in pSS compared with healthy controls, but also in patients with RA and SLE [1315] . In patients with SLE, FLC levels correlate with disease activity and are elevated in urine prior to relapse of symptoms [14, 16] . However, the clinical relevance of serum FLC levels as a biomarker in pSS is unclear. The objectives of this study were to assess if serum FLCs can contribute to classification, MALT lymphoma detection, monitoring of disease activity and treatment response in pSS.
Methods

Study population
Consecutive patients (n = 129), referred to the Sjö gren Expertise Center of the University Medical Center Groningen (UMCG) for suspicion of pSS, were screened for eligibility. Exclusion criteria were age <18 years, an incomplete diagnostic work-up, diagnosis of another systemic auto-immune disease, hepatitis C positivity and renal impairment (estimated glomerular filtration rate < 60 ml/min, Modification of Diet in Renal Disease formula), which influences serum FLC levels [9] . Patients that fulfilled 2016 ACR-EULAR criteria for pSS were classified as pSS patients [17] , and the remaining patients as non-SS sicca patients. Serum samples of 18 consecutive pSS patients with a current or pre-existing diagnosis of salivary gland MALT lymphoma, who were enrolled as a subgroup in our REgistry of Sjö gren syndrome in Umcg-Longitudinal cohort, were also screened for eligibility. Of these 18 patients, one was excluded from FLC analysis because of renal impairment. The remaining 17 pSS-MALT patients were divided into a rituximab treatment group (rituximab treatment <1 year before inclusion) and a no-treatment group (untreated patients and patients who were treated with rituximab >1 year before inclusion). Informed consent was obtained from all patients according to the Declaration of Helsinki and the studies were approved by the Medical Research Ethics Committee of the UMCG (METc2013.066/METc2014.491).
Additionally, longitudinal serum samples of pSS patients that participated in our previously reported double-blind, randomized controlled trial with rituximab (1000 mg, days 1 and 15, n = 30 with 2:1 randomization for rituximab and placebo) and open-label study with abatacept ($10 mg/kg body weight, days 1, 15 and 29 and every 4 weeks thereafter, n = 15) were included [18, 19] . One patient in the placebo-arm of the rituximab study was lost to follow-up after week 12 and therefore no samples were available from this patient at weeks 24, 36 and 48. To minimize the risk of infusion reactions and serum sickness, all patients in the rituximab and placebo arms were treated with methylprednisolone (100 mg i.v.), acetaminophen (1000 mg orally) and clemastine (2 mg i.v.) prior to each infusion, and received oral prednisone (60 mg on days 1 and 2, 30 mg on days 3 and 4 and 15 mg on day 15). Except for these precautionary medications, treatment with concomitant immunosuppressants, including HCQ and glucocorticoids, was discontinued during the study. All patients that participated in the rituximab and abatacept studies also fulfilled, retrospectively, the ACR-EULAR criteria. The EULAR SS DAI (ESSDAI) and clinESSDAI (ESSDAI without the biological domain) were completed in all pSS patients [20, 21] .
FLC measurement
Stored serum samples (À80 C) were thawed and FLCs (k and ) were measured by quantitative turbidimetry using the Freelite assay and the Optilite analyser (Binding Site, Birmingham, UK). The Freelite assay estimates FLCk and FLC by separate immunoassays based on affinity-purified polyclonal antibodies coated onto latex particles. Samples from the MALT lymphoma group and the rituximab study were measured by quantitative nephelometry using the Freelite assay and the BNProSpec analyzer (Siemens AG, Erlangen, Germany), as part of the diagnostic work-up. Reference intervals were 3.319.4 mg/l for FLCk, 5.726.3 mg/l for FLC and 0.261.65 for the k/ ratio, according to the 95% percentile range provided by the manufacturer. An abnormal FLC level was defined as an abnormal k and/or level and/or abnormal k/ ratio.
Statistical analysis
Continuous data are presented as medians and interquartile ranges. The MannWhitney U test was used to compare FLC levels between different groups. Predictor analyses of pSS classification were performed using https://academic.oup.com/rheumatology binary logistic regression. Multivariate analysis was performed using the forward Wald method for inclusion of predictors that had a P < 0.05 in the univariate analysis. The explained variance is presented as Nagelkerke's R 2 .
Residual statistics were assessed and outlier cases were identified based on Cook's distance >1, or standard and normalized residual values outside the cut-off values of ±1.96 and ±2.58, respectively. Cross-sectional correlations between serum FLCs and clinical and biological parameters (i.e. ESSDAI, clinESSDAI, IgG) were evaluated with Spearman's correlation coefficient. Longitudinal correlations between FLCs and clinical parameters were analysed with generalized estimating equations. Generalized estimating equations were used to analyse changes in FLC levels over time, namely during B cell depletion (weeks 024), during B cell repopulation (weeks 2448), during abatacept treatment (weeks 024) and after cessation of abatacept treatment (weeks 2438). For the placebo group, identical time points were analysed to those for the rituximab group. To evaluate sensitivity to change, the standardized response mean (SRM) was calculated as the mean change score divided by the S.D. of the change score, between baseline and each consecutive time point. SRM < 0.5 was interpreted as small, 0.50.8 as moderate and >0.8 as large [22] . P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS Statistics version 23 (IBM Corp., Armonk, NY, USA).
Results
From the diagnostic cohort, 100 out of 129 patients were included in the analyses. Reasons for exclusion were an incomplete diagnostic work-up (n = 8), presence of another systemic auto-immune disease (n = 12), missing serum samples (n = 5), hepatitis C infection (n = 2) or renal impairment (n = 2). There were no patients with renal impairment in the treatment groups (rituximab, abatacept) at baseline or during follow-up. Baseline patient's characteristics of the different cohorts are summarized in Table 1 . Detailed clinical characteristics of the MALT lymphoma group are described in supplementary Table  S1 , available at Rhematology online.
Elevated FLC levels and k/ ratio in pSS patients at the time of diagnosis Of the included patients from the diagnostic cohort, 45 (45%) patients were classified as having pSS. Twentynine (64%) of these pSS patients had abnormal FLC levels. Both FLCk and FLC levels were significantly increased in pSS compared with non-SS sicca patients ( Fig. 1A and B; P < 0.001). In pSS, FLCk and FLC levels were above the upper reference limits in 58 and 44% of patients, respectively. FLC levels were higher in anti-SSA positive compared with anti-SSA negative patients (P = 0.037 for FLCk, P = 0.064 for FLC). In addition to absolute levels of FLC, the k/ ratio was assessed. A small but significant increase in the k/ ratio was observed in pSS, compared with non-SS sicca patients ( Fig. 1C ; P = 0.009), indicating a slightly higher production of FLCk vs FLC. There was no significant difference in k/ ratio between pSS patients with or without anti-SSA antibodies.
In five (11%) pSS patients and three (5%) non-SS sicca patients, a k/ ratio above the upper cut-off value was found. One of these pSS patients was diagnosed with MALT lymphoma. This patient also presented with abnormal levels of RF (>200 IU/ml), IgG (25 mg/l) and weak type III cryoglobulinaemia (polyclonal), but without lymphopenia or low C4. A second pSS patient with an abnormal k/ ratio had an IgG level of 32 mg/l and developed urticarial vasculitis and unilateral parotid gland swelling a few months after inclusion. A third pSS patient with an abnormal k/ ratio developed progressive neuropathy with lymphopenia, low C4 level and weak type I cryoglobulinaemia (monoclonal) 1 year later during follow-up. In the other two pSS patients and in the three non-SS sicca patients with an abnormal k/ ratio, risk factors for lymphoma such as cryoglobulinaemia, lymphopenia or low complement levels were not detected. Together, these results indicate that an altered k/ ratio may indicate or precede severe clinical manifestations of pSS.
Abnormal k/ ratios in MALT lymphoma patients
Because an abnormal k/ ratio was observed in a MALT lymphoma patient in our diagnostic cohort, these ratios were also evaluated in established pSS patients with salivary gland MALT lymphoma. Seventeen MALT lymphoma patients were included, and five patients were analysed separately because of recent or current B cell depletion therapy. Of the 12 patients who were not treated with rituximab, six (50%) had an abnormal k/ ratio (Fig. 1C) . In only one of these six patients a weak monoclonal immunoglobulin (M-protein) was detected by immunofixation. Of the five patients who were recently treated with rituximab, only one had an abnormal k/ ratio (data not shown). The latter patient with a k/ ratio of 6.2 received maintenance treatment with rituximab every half year, because of recurrent symptoms of vasculitis and polyneuropathy in the past 3 years. Table S2 , available at Rheumatology online). Exclusion of five outliers (see Methods section) improved the predictive value to 0.863, but did not change the independent variables included in the models (data not shown). Together, our results indicate that FLC levels are neither superior nor additional to IgG and anti-SSA positivity as a classification biomarker for pSS.
Association between FLC levels and systemic disease activity at baseline
Previous studies have suggested that FLC levels correlate positively with extraglandular involvement in pSS patients [7, 13] . Consistent with this finding, combined data from our diagnostic cohort and baseline data from the rituximab and abatacept trials, in which ESSDAI scores were relatively high ( Table 1) , indicated that FLCk, and to a lesser extent also FLC, correlated significantly with ESSDAI scores (Fig. 2A) . The ESSDAI domain that showed the highest correlation with FLC levels was the biological domain, which can be explained by the strong correlations between IgG and FLCk and FLC (r = 0.685 and r = 0.621, respectively). Therefore, also correlations between FLCs and clinESSDAI were assessed and only
FIG. 1 Serum levels of FLCk (A) and FLC (B) and the k/ ratio (C) in pSS patients and non-SS sicca patients
FLC levels in a diagnostic cohort consisting of non-SS sicca patients (n = 55) and pSS patients (n = 45), classified according to the ACR-EULAR criteria, are displayed. In addition, results from established pSS patients with mucosaassociated lymphoid tissue (MALT) lymphoma located in the salivary glands, without or with current/recent (<1 year) B cell depletion therapy, are displayed (n = 12 and n = 5, respectively). Horizontal lines indicate the median. Dashed horizontal lines indicate the cut-off value(s). Orange triangles represent patients with salivary gland MALT lymphoma without current/recent B cell depletion therapy; blue triangles represent patients with salivary gland MALT lymphoma who have been treated with B cell depletion therapy <1 year before inclusion. MannWhitney U test was used for statistical comparisons between pSS and non-SS sicca patients. *P-values with asterisk were calculated using one-way analysis of variance (Kruskal-Wallis) comparing pSS, untreated pSS-MALT and treated pSS-MALT patients. P < 0.05 was considered significant. FLC: free light chain; ns: not significant.
FLCk was significantly correlated to clinESSDAI scores, although a trend was seen for FLC (Fig. 2B ).
FLC levels are affected by immunomodulatory treatment
Rituximab
In the group of rituximab-treated and placebo-treated patients, 19 (63%) patients had abnormal FLC levels at baseline, which is comparable to the diagnostic cohort. None of the patients had an abnormal k/ ratio. Median values are displayed in Table 1 . No patients had monoclonal gammapathy, and no MALT lymphoma patients were included in this treatment study. Rituximab reduced both FLCk and FLC levels significantly over time (Fig. 3A) . In placebo-treated patients, FLCs also decreased significantly over time (Fig. 3B ), which could be attributed to a drop only at week 5. In line with this notion, the decrease in FLCs in the rituximab group over time was stronger, of longer duration and significantly different from the placebo group (P < 0.001 for both FLCk and FLC). Furthermore, during B cell repopulation in the rituximab group, FLCk and FLC levels increased to baseline values (Fig. 3A) , whereas no changes were seen in the placebo group between weeks 24 and 48 (Fig. 3B) . Relative changes in FLCk and FLC after 24 weeks of treatment with rituximab were higher compared with IgG (median Á À28, À24 and À21%, respectively). SRM values for responsiveness were large (>0.8) for both FLCs in the rituximab group, persisting until week 36 for FLCk and week 24 for FLC (Fig. 4A ). In the placebo group, a high SRM was found only at week 5 (Fig. 4B) .
Abatacept
At baseline, 14 (93%) patients had abnormal FLC levels, which is higher compared with the diagnostic cohort and the rituximab group. Three (15%) patients had an abnormal k/ ratio. Serum FLC levels were reduced by abatacept treatment (Fig. 3C) . Levels of FLCk decreased to a larger extent than FLC (Fig. 3C) . Median relative changes between baseline and week 24 for FLCk, FLC and IgG were À18, À10 and À12%, respectively,
FIG. 2 Correlations between FLCs and systemic disease activity
Correlations between FLCs and systemic disease activity, as measured by ESSDAI (A) and clinESSDAI (B), in 90 pSS patients classified according to ACR-EULAR criteria. Patients with pSS from the diagnostic cohort (n = 45) and baseline data from the rituximab (n = 30) and abatacept (n = 15) cohorts were combined. Correlations were evaluated with Spearman's correlation coefficient (r). FLC: free light chain.
indicating that FLCk was most strongly reduced by abatacept treatment. SRM values were larger for FLCk than FLC (Fig. 4C) .
Associations between changes in FLC levels and systemic disease activity during treatment Finally, we assessed if the observed changes in FLC levels correlated with clinical and biological parameters over time during treatment, namely the period of B cell depletion by rituximab, and the period of treatment with abatacept (both weeks 024). We performed the same analyses for the period after treatment (weeks 2448). The decrease in FLCk and FLC in the rituximab group was significantly associated with lowering of ESSDAI and clinESSDAI scores from baseline to week 24 (Table 2) . Weaker correlations were observed in the placebo group (Table 2 ). In the abatacept group, only FLCk was significantly associated with ESSDAI and clinESSDAI scores over time during treatment (weeks 024). Also after treatment, in the rituximab group, FLCk and FLC levels correlated significantly with ESSDAI/clinESSDAI scores ( Table 2 ), suggesting that the increase in both parameters after treatment occurs in a similar manner.
Discussion
Serum FLCs are biomarkers for actual B cell activity and are frequently elevated in systemic autoimmune diseases [13, 15] . This study shows that serum FLCk and FLC levels are elevated in pSS patients, compared with non-SS sicca patients, at the time of diagnosis. Importantly, we found that an abnormal FLC k/ ratio can be indicative for the presence of MALT lymphoma. This study further shows that FLC levels rapidly decrease following treatment with rituximab or abatacept, and that these levels are associated with systemic disease activity at baseline and longitudinally in response to treatment. In our diagnostic cohort, FLCk and FLC levels were abnormal in 58 and 44% of patients, respectively. This percentage is considerably higher than the previously reported percentages of 2224% by Gottenberg et al. [7, 13] . This difference may be explained by higher B cell activity in our cohort, reflected by higher IgG levels and/ or by the lower frequency of immunosuppressive drug use in our cohort. In line with a previous study by Sudzius et al. [23] , we observed that increased FLC levels were more pronounced in anti-SSA-positive compared with anti-SSA-negative pSS patients, suggesting that patients with anti-SSA antibodies exhibit higher B cell activity and hence produce more FLCs. We also found a subtle, but significant increase in the k/ ratio in pSS patients, though only 11% of the pSS patients had an abnormal ratio according to the 95-percentile range [7] . The reason for this skewing is not clear, but one possibility is that it is due to the autoantibody status, indicating that autoreactive B cells might express relatively more k than chains. However, no difference in the k/ ratio was observed between anti-SSA-positive and -negative patients, in line with a previous report [23] . In addition to anti-SSA/-SSB antibodies, pSS patients frequently produce RF. RF positivity in pSS is associated with a higher risk of lymphoma development [24] . Bende et al. [25] showed that 41% of salivary gland MALT lymphomas expressed B cell receptors with strong RF homology. Interestingly, the vast majority of these lymphomas were typed as k-predominant by immunohistochemistry. These data suggest that RF-producing B cells may contribute to the skewed k/ ratio in a subgroup of pSS patients. Because one of the pSS patients with an abnormal k/ ratio in our diagnostic cohort was diagnosed with MALT lymphoma, we evaluated FLC levels in a cohort of established pSS patients with MALT lymphoma located in the salivary gland. A previous study by Witzig et al. [26] revealed elevated FLC levels in 31% of MALT lymphoma patients, but lymphoma localization was not specified. Whether also salivary gland MALT lymphomas in pSS patients present with abnormal FLC levels and/or ratios is to the best of our knowledge not known. Our study shows that the k/ ratio was increased in 50% of patients with salivary gland MALT lymphoma. In only one of the 12 (8%) pSS patients with MALT lymphoma a weak M-protein was detectable, indicating that secretion of complete immunoglobulins occurs only infrequently. A similar low frequency (9%) of M-protein in pSS-MALT patients was revealed by Wö hrer et al. [27] , whereas we showed previously that M-proteins were present in 8 out of 35 (23%) pSS-MALT patients [28] . Recent studies showed that the frequencies of monoclonal gammopathy in larger cohorts of pSS patients were 7.422% [29, 30] . However, only a few of the patients with M-proteins (06%) developed salivary gland MALT lymphoma (follow-up time 6.310 years). These data strongly argue that the k/ ratio in serum may be more useful as an indicator for the presence of MALT lymphoma than finding an M-protein. This situation is analogous to patients with a monoclonal gammopathy of unknown significance in which the risk of progression to a malignant monoclonal gammopathy is higher in patients with an abnormal k/ ratio than in patients with a normal ratio [31] . In contrast to other pSS lymphoma cohorts [8, 32] , the median ESSDAI score in our pSS-MALT cohort was relatively low. This may be explained by the fact that in our clinical work-up parotid gland biopsies are taken for diagnostic purposes. This setting results in unexpected detection of MALT lymphoma in patients with low disease activity, as shown previously [28] . A second, not mutually exclusive, explanation could be that both patients with a current or pre-existing MALT lymphoma diagnosis were included. The finding that patients with a pre-existing MALT lymphoma diagnosis frequently present with abnormal k/ ratios suggests that this biomarker may also be useful as an indicator of MALT lymphoma persistence and/or recurrence. Recurrence appears in 2935% of the parotid gland MALT lymphoma cases [28, 33] .
In addition to the findings in pSS-MALT patients, our study confirmed that abnormal FLC levels in pSS are associated with higher systemic disease activity, as measured by ESSDAI scores [7] . The biological domain of the ESSDAI score also includes elevated serum IgG levels, which obviously may bias the correlation between FLC levels and ESSDAI. For this reason we correlated FLC levels not only to ESSDAI, but also to clinESSDAI scores [20] . Interestingly, FLCk was significantly and more strongly correlated to both ESSDAI and clinESSDAI scores than FLC. Thus, increased disease activity of pSS is not only associated with increased polyclonal B cell activity, but remarkably also with preferential expansion of the k-subtype, which is confirmed in other studies in pSS [7, 8, 13] . The reason for this preferential expansion remains obscure.
Besides a role as biomarker for systemic disease activity, FLCs are potentially useful in monitoring the effect of immunomodulatory treatment on B cell activity in pSS patients. Therefore, the effect of treatment with rituximab and abatacept on serum FLC levels was evaluated. Rituximab treatment significantly reduced FLCk and FLC levels, reflecting the decreased number of antibody-secreting cells (i.e. B cells, plasmablasts, plasma cells). A reduction in FLCs was also seen in the placebo group at week 5, likely due to corticosteroid treatment around the rituximab infusions, but a significantly stronger decrease was observed in the rituximab group. The decrease in FLCs correlated significantly with lowering of ESSDAI and clinESSDAI during B cell depletion. These findings are consistent with studies in RA and SLE showing a correlation between normalization of FLC levels and disease activity upon rituximab treatment [34, 35] . We found that abatacept treatment also significantly reduced FLCk and, to a smaller extent, FLC levels. FLCk levels were significantly associated with ESSDAI and clinESSDAI scores over time during treatment. As B cells are not directly targeted by abatacept, the observed decrease in FLCs is likely a result of reduced T cell help to B cells. This is further substantiated by the previously observed decrease in serum levels of IgG, anti-SSA antibodies and RF, as well as circulating plasmablasts [19, 36] . Additionally, our study reveals that FLCs have a large sensitivity to change, assessed by SRM, and that relative changes in FLCk were higher compared with IgG. An advantage of monitoring FLCs is that changes in serum levels are more rapidly induced after initiation of treatment, compared with IgG. FLCs have a half-life of several hours, while IgG has a half-life of several weeks [9] . Therefore, B cell activity can be monitored by FLC levels without the delay that is seen for IgG.
In summary, this study shows for the first time that the k/ ratio in serum is abnormal in 50% of salivary gland MALT lymphoma patients. Abnormal ratios should be taken seriously and might be indicative for the presence, persistence and/or recurrence of MALT lymphoma. Prospective analysis of the k/ ratio in pSS patients is necessary to confirm its potential role as predictor of MALT lymphoma development, and to compare sensitivity with M-protein analysis. Moreover, our data underline the pathogenic role of B cell hyperactivity, and particularly k-expressing B cells, in pSS. Finally, we suggest that FLCs are useful biomarkers to monitor the effect of immunomodulatory treatment on B cell activity.
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